Abstract
Stimulation of Group I metabotropic glutamate receptors (mGluR1 and mGluR5) leads to activation of a wide variety of signalling pathways. mGluRs couple to Gαq/11 proteins, activating phospholipase Cβ1 resulting in both diacylglycerol and inositol-1,4,5- triphosphate formation followed by the activation of protein kinase C. In addition, mGluR activation can lead to modulation of a number of ion channels, such as different types of calcium and potassium channels. Group I mGluRs can also activate other downstream protein kinases, such as ERK1/2 and AKT, which are implicated in cellular growth, differentiation, and survival. Moreover, Group I mGluRs interact with a variety of different proteins that are important for the regulation of synaptic signalling, such as Homer and PDZ domain containing proteins, such as Tamalin. A role for mGluR1/5 in a number of disease states has also been proposed. As mGluR1/5 signal transduction is complex and involves multiple partners, a better understanding of alterations in mGluR signalling in brain disorders will be required in order to discern the molecular and cellular basis of these pathologies. This review will highlight recent findings concerning mGluR signaling alterations in brain pathologies, such as stroke, fragile X syndrome, Alzheimers disease, Parkinsons disease, Huntingtons disease, epilepsy, and drug addiction.
Keywords: Metabotropic glutamate receptors, mGluR1/5, Gαq/11 proteins, stroke, fragile X syndrome, Alzheimer's disease, Parkinson's disease, Huntington's disease, epilepsy, drug addiction
CNS & Neurological Disorders - Drug Targets
Title: Group I Metabotropic Glutamate Receptor Signalling and its Implication in Neurological Disease
Volume: 9 Issue: 5
Author(s): Fabiola M. Ribeiro, Maryse Paquet, Sean P. Cregan and Stephen S. G. Ferguson
Affiliation:
Keywords: Metabotropic glutamate receptors, mGluR1/5, Gαq/11 proteins, stroke, fragile X syndrome, Alzheimer's disease, Parkinson's disease, Huntington's disease, epilepsy, drug addiction
Abstract: Stimulation of Group I metabotropic glutamate receptors (mGluR1 and mGluR5) leads to activation of a wide variety of signalling pathways. mGluRs couple to Gαq/11 proteins, activating phospholipase Cβ1 resulting in both diacylglycerol and inositol-1,4,5- triphosphate formation followed by the activation of protein kinase C. In addition, mGluR activation can lead to modulation of a number of ion channels, such as different types of calcium and potassium channels. Group I mGluRs can also activate other downstream protein kinases, such as ERK1/2 and AKT, which are implicated in cellular growth, differentiation, and survival. Moreover, Group I mGluRs interact with a variety of different proteins that are important for the regulation of synaptic signalling, such as Homer and PDZ domain containing proteins, such as Tamalin. A role for mGluR1/5 in a number of disease states has also been proposed. As mGluR1/5 signal transduction is complex and involves multiple partners, a better understanding of alterations in mGluR signalling in brain disorders will be required in order to discern the molecular and cellular basis of these pathologies. This review will highlight recent findings concerning mGluR signaling alterations in brain pathologies, such as stroke, fragile X syndrome, Alzheimers disease, Parkinsons disease, Huntingtons disease, epilepsy, and drug addiction.
Export Options
About this article
Cite this article as:
M. Ribeiro Fabiola, Paquet Maryse, P. Cregan Sean and S. G. Ferguson Stephen, Group I Metabotropic Glutamate Receptor Signalling and its Implication in Neurological Disease, CNS & Neurological Disorders - Drug Targets 2010; 9 (5) . https://dx.doi.org/10.2174/187152710793361612
DOI https://dx.doi.org/10.2174/187152710793361612 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Anticonvulsant Activity Of Benzylamides Of Some Amino Acids And Heterocyclic Acids
Protein & Peptide Letters The Mutual Interaction Between Sleep and Epilepsy on the Neurobiological Basis and Therapy
Current Neuropharmacology Trypanosomatid Parasites Causing Neglected Diseases
Current Medicinal Chemistry Diabetes, Cognitive Function, and the Blood-Brain Barrier
Current Pharmaceutical Design Metabolic Regulation of Uridine in the Brain
Current Metabolomics Poor Safety and Tolerability Hamper Reaching a Potentially Therapeutic Dose in the Use of Thalidomide for Alzheimer’s Disease: Results from a Double-Blind, Placebo-Controlled Trial
Current Alzheimer Research Metallocarboxypeptidases and their Inhibitors: Recent Developments in Biomedically Relevant Protein and Organic Ligands
Current Medicinal Chemistry New Medical Strategies for Midgut Carcinoids
Anti-Cancer Agents in Medicinal Chemistry Novel Medication Targets for the Treatment of Alcoholism: Preclinical Studies
Recent Patents on CNS Drug Discovery (Discontinued) Targeting Cytokines for Morphine Tolerance: A Narrative Review
Current Neuropharmacology Targeting Voltage-Gated Sodium Channels for Treating Neuropathic and Inflammatory Pain
Current Pharmaceutical Biotechnology Strategies for Strengthening Patent Protection of Pharmaceutical Inventions in Light of Federal Court Decisions
Current Topics in Medicinal Chemistry The Benefit of Prescribing Vitamin D as Add on Therapy on the Electrocardiographic Changes in Epileptic Patients
Current Clinical Pharmacology Towards a Causal Model for Disgust in the Anxiety Disorders: An Integration of Evidence from Neuroscience
Current Psychiatry Reviews Synthesis and Anticonvulsant Activity of 7-Alkoxy-Triazolo-[3, 4-b] Benzo[d]Thiazoles
Medicinal Chemistry Substituted Aminobenzothiazole Derivatives of Tacrine: Synthesis and Study on Learning and Memory Impairment in Scopolamine-Induced Model of Amnesia in Rat
Mini-Reviews in Medicinal Chemistry Conventional (Continuous) EEG Monitoring in the NICU
Current Pediatric Reviews Concise Synthesis of Non-Protein Amino Acid from Natural Product via Schmidt Reaction
Letters in Organic Chemistry The Potential Role of Pro-Inflammatory and Anti-Inflammatory Cytokines in Epilepsy Pathogenesis
Endocrine, Metabolic & Immune Disorders - Drug Targets Editorial [Hot topic: The Urokinase Receptor System as Strategic Therapeutic Target: Challenges for the 21st Century (Executive Guest Editor: Bernard Degryse)]
Current Pharmaceutical Design